PGEN

Analyst Recommendation: HC Wainwright & Co. maintains a Buy recommendation for Precigen (NasdaqGS:PGEN), with a projected one-year price target of $8.42/share, indicating a potential upside of 73.68% from its current price of $4.84/share.

Revenue and Earnings Projections: Precigen's projected annual revenue is expected to reach $59 million, reflecting an increase of 829.62%, with a projected non-GAAP EPS of 0.20.

Institutional Ownership Trends: There has been an increase in institutional ownership of Precigen, with 277 funds reporting positions, a rise of 8.63% in the last quarter, and total shares owned increasing by 28.21% to 133,539K shares.

Shareholder Activity: Notable changes in shareholder positions include Patient Capital Management increasing its stake by 38.52%, while LMORX - Patient Opportunity Trust Class R reduced its holdings by 6.25%.

Put Selling Mechanics: Selling a put option does not provide the same upside potential as owning shares, as the seller only acquires shares if the contract is exercised, which occurs if the stock price drops significantly.

Counterparty Risk and Returns: The put seller's only benefit is the premium collected, which offers a 12.4% annualized return unless the stock declines enough to trigger the exercise of the option.

Volatility and Analysis: The historical volatility of Precigen Inc is calculated at 104%, which, along with fundamental analysis, can help assess the risk-reward balance of selling the January 2028 put option at a $3.50 strike price.

Market Context: The article emphasizes the importance of understanding options trading dynamics and the specific market conditions surrounding Precigen Inc's stock performance.

Vaxart's Financial Performance: Vaxart's shares rose ~11% after reporting Q3 revenue of $72.4M, exceeding forecasts by $32.3M, largely due to a BARDA contract. The company also noted a net loss per share of $0.04, reflecting a ~33% YoY contraction despite a significant increase in R&D expenses.

Precigen's Growth and FDA Approval: Precigen's shares surged ~27% following a strong Q3 performance with $2.9M in revenue, surpassing expectations and showing over 200% YoY growth, driven by collaboration and licensing revenue after FDA approval of its immunotherapy candidate, Papzimeos.

Patient Engagement for Papzimeos: Since receiving FDA approval in August, Precigen has registered over 100 patients in its Papzimeos Patient Hub, indicating strong early interest and rapid activation of its sales force.

Rising Costs for Both Companies: Both Vaxart and Precigen reported increased net losses per share, with Precigen's SG&A and R&D costs rising significantly, highlighting the financial pressures associated with their respective development activities.